Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin‐Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin‐Resistant Strains
Authors:
- Javier Molina‐InfanteJMJavier Molina‐Infante
- Carmen Pazos‐PachecoCPCarmen Pazos‐Pacheco
- Gema Vinagre‐RodriguezGVGema Vinagre‐Rodriguez
- Belen Perez‐GallardoBPBelen Perez‐Gallardo
- Carmen Dueñas‐SadornilCDCarmen Dueñas‐Sadornil
- Moisés Hernandez‐AlonsoMHMoisés Hernandez‐Alonso
- Guadalupe Gonzalez‐GarciaGGGuadalupe Gonzalez‐Garcia
- Jose M. Mateos‐RodriguezJMJose M. Mateos‐Rodriguez
- Miguel Fernandez‐BermejoMFMiguel Fernandez‐Bermejo
- Javier P. GisbertJGJavier P. Gisbert
- MoisésMOMoisés
- 30 March 2012
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 17 (4) , 269-276
Abstract
Background: Using quadruple clarithromycin‐containing regimens for Helicobacter pylori eradication is controversial with high rates of macrolide resistance.Aim: To evaluate antibiotic resistance rates and the efficacy of empirical and tailored nonbismuth quadruple (concomitant) therapy in a setting with cure rates Methods: 209 consecutive naive H. pylori‐positive patients without susceptibility testing were empirically treated with 10‐day concomitant therapy (proton pump inhibitors (PPI), amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg; all drugs b.i.d.). Simultaneously, 89 patients with positive H. pylori culture were randomized to receive triple versus concomitant therapy for clarithromycin‐susceptible H. pylori, and sequential versus concomitant therapy for clarithromycin‐resistant strains. Eradication was confirmed with 13C‐urea breath test or histology 8 weeks after completion of treatment.Results: Per‐protocol (PP) and intention‐to‐treat eradication rates after empirical concomitant therapy without susceptibility testing were 89% (95%CI:84–93%) and 87% (83–92%). Antibiotic resistance rates were: clarithromycin, 20%; metronidazole, 34%; and both clarithromycin and metronidazole, 10%. Regarding clarithromycin‐susceptible H. pylori, concomitant therapy was significantly better than triple therapy by per protocol [92% (82–100%) vs 74% (58–91%), p = 0.05] and by intention to treat [92% (82–100%) vs 70% (57–90%), p = 0.02]. As for antibiotic‐resistant strains, eradication rates for concomitant and sequential therapies were 100% (5/5) vs 75% (3/4), for clarithromycin‐resistant/metronidazole‐susceptible strains and 75% (3/4) vs 60% (3/5) for dual‐resistant strains.Conclusions: Empirical 10‐day concomitant therapy achieves good eradication rates, close to 90%, in settings with multiresistant H. pylori strains. Tailored concomitant therapy is significantly superior to triple therapy for clarithromycin‐susceptible H. pylori and at least as effective as sequential therapy for resistant strains.Keywords
This publication has 34 references indexed in Scilit:
- Evaluation of a Four‐drug, Three‐antibiotic, Nonbismuth–containing “Concomitant” Therapy as First‐line Helicobacter pylori Eradication Regimen in GreeceHelicobacter, 2012
- 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trialThe Lancet, 2011
- Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trialThe Lancet, 2011
- Helicobacter pylori treatment in the era of increasing antibiotic resistanceGut, 2010
- Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori InfectionClinical Gastroenterology and Hepatology, 2010
- Meta‐analysis: Four‐Drug, Three‐Antibiotic, Non‐bismuth‐Containing “Concomitant Therapy” Versus Triple Therapy for Helicobacter pylori EradicationHelicobacter, 2009
- New concepts of resistance in the treatment of Helicobacter pylori infectionsNature Clinical Practice Gastroenterology & Hepatology, 2008
- American College of Gastroenterology Guideline on the Management of Helicobacter pylori InfectionAmerican Journal of Gastroenterology, 2007
- The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysisGut, 2007
- Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut, 2007